Combinational Therapy in Triple Negative Breast Cancer
- 1st Edition - April 28, 2022
- Imprint: Academic Press
- Author: Manzoor Ahmad Mir
- Language: English
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 9 6 1 3 6 - 3
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 6 1 3 7 - 0
Combinational Therapy in Triple Negative Breast Cancer discusses TNBC at the molecular level from a holistic approach, focusing on combinational strategies targeting various p… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteCombinational Therapy in Triple Negative Breast Cancer discusses TNBC at the molecular level from a holistic approach, focusing on combinational strategies targeting various pathways involved in this specific cancer type. Using a monotherapy for the treatment of cancer, especially high-grade tumors like TNBC, is mostly worthless due to the inherent genetic instability of tumor cells to develop intrinsic and acquired resistance. Combination therapy presents more, or at least the same, effectiveness with lower doses of every single agent and decreases the likelihood of chemoresistance, making it essential to understand for multiple therapy options.
The book is a valuable resource for cancer researchers, oncologists, graduate students and members of the biomedical field who are interested in the potential of combinational therapies to treat triple negative breast cancer.
- Presents up-to-date and cutting-edge knowledge of Triple negative breast cancer (TNBC) biology, clinical aspects and treatment options
- Discusses novel targets and pathways involved in TNBC
- Provides insights and approaches for future research on TNBC
Researchers and graduate students on cancer research
Oncologists, medical doctors
- Cover Image
- Title Page
- Copyright
- Table of Contents
- Contributors
- About the author
- Foreword
- Preface
- Acknowledgments
- Chapter 1 Triple-negative breast cancer - an aggressive subtype of breast cancer
- Introduction
- Triple-negative breast cancer (TNBC)
- TNBC histological classification
- TNBC molecular classification
- Triple-negative breast cancer risk factors and epidemiology
- Current diagnostic options for triple-negative breast cancer
- Future diagnostic options for TNBC
- Triple-negative breast cancer’s prognostic implications
- Somatic genomic mutations in TNBC
- Epigenetic modifications in TNBC
- Summary
- References
- Chapter 2 Novel biomarkers in triple-negative breast cancer - role and perspective
- Introduction
- EGFR
- VEGF
- PARP
- Summary
- References
- Chapter 3 Current therapeutics and treatment options in TNBC
- Introduction
- Signaling pathways involved in triple-negative breast cancer (TNBC) treatment
- Role of chemotherapeutic agents in TNBC
- Surgery and radiotherapy
- Targeted therapeutics for TNBC
- Role of immunotherapy in the treatment of TNBC
- Advanced treatment options for TNBC
- Summary
- References
- Chapter 4 Conventional adjuvant chemotherapy in combination with surgery, radiotherapy, and other specific targets
- Introduction
- An overview of chemotherapy
- Adjuvant chemotherapy: First, second, and third generation regimens
- The case for chemotherapy in TNBC
- Surgery in TNBC
- Radiotherapy in TNBC
- Chemotherapy combining specific target molecules in TNBC
- EGFR
- Summary
- References
- Chapter 5 Role of immune system in TNBC
- Introduction
- Cancer-immunity cycle
- Immune system in cancer –a friend or FOE
- Immune system and TNBC
- Immune checkpoints in TNBC
- Newly emerging immune checkpoints
- TIM/CEACAM1-L
- TNBC metastasis and recurrence
- Summary
- References
- Chapter 6 The interplay of immunotherapy, chemotherapy, and targeted therapy in tripple negative breast cancer (TNBC)
- Introduction
- An overview of immunotherapy in TNBC
- Immunotherapy’s potential in TNBC: Variables to be considered
- Choosing the proper immunotherapy and chemotherapy combination
- Immune checkpoint blockades in TNBC
- Combination treatments involving PD1/PD-L1
- Adoptive cell therapy
- Cancer vaccines
- Resistance to ICI
- Moving immunotherapy to early TNBC
- Efficacy of immunotherapy and future perspectives in TNBC
- Summary
- References
- Chapter 7 Targeting biologically specific molecules in triple negative breast cancer (TNBC)
- Introduction
- An overview of targeted therapy
- Experimental targets for TNBC under study
- Summary
- References
- Chapter 8 Different drug delivery approaches in combinational therapy in TNBC
- Introduction
- Nanocarriers as targeted drug delivery systems
- Ligands for targeted TNBC treatment
- VLPS (virus-like particles) as unique nanocarriers
- Role of nanomedicine in breast cancer treatment: A transition from traditional to nanomedicine
- Gene delivery
- Photothermal therapy
- Photodynamic therapy
- Nanosoldiers to suppress TNBC metastasis
- Stimulus responsive drug delivery
- Summary
- References
- Glossary
- Abbreviations
- Index
- Edition: 1
- Published: April 28, 2022
- No. of pages (Paperback): 276
- No. of pages (eBook): 276
- Imprint: Academic Press
- Language: English
- Paperback ISBN: 9780323961363
- eBook ISBN: 9780323961370
MM
Manzoor Ahmad Mir
Dr. Manzoor Ahmad Mir holds a Master’s Degree in Zoology from HNBG Central University and completed his Ph.D. in Immunology at Jawaharlal Nehru University, New Delhi, and CSIR-Institute of Microbial Technology, Chandigarh. His research focuses on Cancer Biology, Combination Therapy in Breast Cancer, and Tuberculosis Immunology. Dr. Mir has published over 50 high-impact research papers and book chapters, earning multiple awards and royalties. He has authored more than 15 books with international publishers like Elsevier and Springer-Nature. Dr. Mir serves on the editorial boards of prestigious journals and has been an invited speaker at numerous scientific conferences. He is a member of several scientific organizations, including the American Association of Cancer Research and the Royal British Society. He has received the TARE Fellowship and the SRFP-2019 from Indian science academies. Dr. Mir teaches Cancer Biology and Immunology at the University of Kashmir, where he heads the Department of Bioresources.
Affiliations and expertise
Department of Bioresources, School of Biological Sciences, University of Kashmir, Srinagar, IndiaRead Combinational Therapy in Triple Negative Breast Cancer on ScienceDirect